Work

Fludarabine, Melphalan, 4Gy TBI Conditioning for High-Risk Haplo-Cord Transplantation Is Well Tolerated and Results in Prompt Engraftment

Year: 2016

Type: article

Abstract: To reduce early relapse and the possibility of graft rejection in the highest-risk, heavily pre-treated patients receiving haplo-cord transplants, we studied the addition of 4Gy TBI to the RIC regimen of fludarabine, melphalan, and rATG. 24 pts with AML (12), ALL (6), NHL (2), CML in chronic phase 2 (2), Hodgkin’s lymphoma (1), or severe AA (1) (median age 53.9 (range 19-70) yrs; 11 females, 13 males) underwent haplo-cord SCT between May 2013 and March 2015 with fludarabine 30mg/m2 on D-7 to -3, melphalan 140mg/m2 on D-2, and 2Gy TBI on D-4 and -3.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2015.11.778

Authors: Hannah Choe, Koen van Besien

Institution: Weill Cornell Medicine

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650